Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

Jean‐Luc Raoul

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6305-8953; OpenAlex author ID A5079660535. Sources: ClinicalTrials.gov.

Their work

Papers
22 (first author 1, last author 5)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2011: 2 papers, 1 trial · 2012: 1 paper · 2013: 1 paper, 1 trial · 2014: 1 trial · 2015: 4 papers · 2016: 5 papers · 2017: 6 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 22

  1. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  2. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Co-author DOI 10.1016/j.suronc.2018.07.014↗
  3. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  4. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  5. How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017? First author DOI 10.1016/j.jgo.2017.08.007↗
  6. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Last author DOI 10.1097/md.0000000000006544↗
  7. Prognostic Value of Molecular Subtypes in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000787↗
  8. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. Co-author DOI 10.1186/s12916-017-0936-z↗
  9. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  10. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. Last author DOI 10.1007/s12029-015-9774-4↗
  11. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  12. Prognostic value of PDL1 expression in pancreatic cancer. Co-author DOI 10.18632/oncotarget.11685↗
  13. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. Last author DOI 10.18632/oncotarget.9861↗
  14. Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. Co-author PMID 27107061↗
  15. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2014.11.029↗
  16. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  17. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Co-author DOI 10.18632/oncotarget.2685↗
  18. [Management of localized, locally advanced and metastatic pancreatic adenocarcinoma]. Last author PMID 26016202↗
  19. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomize… Co-author DOI 10.1200/jco.2012.44.4869↗
  20. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … Last author DOI 10.1093/annonc/mds135↗
  21. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗
  22. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Co-author DOI 10.1186/1471-2407-11-346↗

Trials 3

  1. Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer Principal investigator NCT02174887↗
  2. Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic Adenocarcinomas Principal investigator NCT02487836↗
  3. NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer Principal investigator NCT01521702↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marine Gilabert · 13 shared papers, 2012–2018 · strength 0.78
  2. Olivıer Turrini · 13 shared papers, 2012–2018 · strength 0.70
  3. Jean‐Robert Delpéro · 9 shared papers, 2011–2018 · strength 0.48
  4. Marc F. Giovannini · 8 shared papers, 2012–2017 · strength 0.36
  5. Daniel Birnbaum · 4 shared papers, 2016–2017 · strength 0.24
  6. François Bertucci · 4 shared papers, 2016–2017 · strength 0.24
  7. Émilie Mamessier · 4 shared papers, 2016–2017 · strength 0.24
  8. David Jérémie Birnbaum · 4 shared papers, 2016–2017 · strength 0.24
  9. Juan Iovanna · 5 shared papers, 2015–2017 · strength 0.22
  10. Frédérique Rousseau · 2 shared papers, 2016–2017 · strength 0.18
  11. Laurence Moureau-Zabotto · 3 shared papers, 2012–2018 · strength 0.17
  12. Céline Loncle · 4 shared papers, 2015–2017 · strength 0.17
  13. Véronique Secq · 4 shared papers, 2015–2017 · strength 0.17
  14. Odile Gayet · 4 shared papers, 2015–2017 · strength 0.17
  15. Mehdi Ouaïssi · 4 shared papers, 2015–2017 · strength 0.17
  16. Nelson Dusetti · 4 shared papers, 2015–2017 · strength 0.17
  17. Anthony Gonçalvès · 4 shared papers, 2012–2017 · strength 0.14
  18. Petr Kavan · 2 shared papers, 2017–2018 · strength 0.13
  19. Pauline Duconseil · 3 shared papers, 2015–2017 · strength 0.12
  20. Sandrine Oziel-Taïeb · 2 shared papers, 2016 · strength 0.12
  21. Jean‐Baptiste Bachet · 3 shared papers, 2011–2018 · strength 0.11
  22. Marc Ychou · 3 shared papers, 2011–2018 · strength 0.11
  23. Thierry Conroy · 3 shared papers, 2011–2018 · strength 0.11
  24. Rémy Nicolle · 2 shared papers, 2017 · strength 0.09
  25. Benjamin Bian · 2 shared papers, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.